157 related articles for article (PubMed ID: 16672229)
1. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.
Gårdsvoll H; Gilquin B; Le Du MH; Ménèz A; Jørgensen TJ; Ploug M
J Biol Chem; 2006 Jul; 281(28):19260-72. PubMed ID: 16672229
[TBL] [Abstract][Full Text] [Related]
2. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
Gårdsvoll H; Danø K; Ploug M
J Biol Chem; 1999 Dec; 274(53):37995-8003. PubMed ID: 10608868
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
4. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
5. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
6. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Ploug M; Østergaard S; Gårdsvoll H; Kovalski K; Holst-Hansen C; Holm A; Ossowski L; Danø K
Biochemistry; 2001 Oct; 40(40):12157-68. PubMed ID: 11580291
[TBL] [Abstract][Full Text] [Related]
7. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
8. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
10. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
13. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
14. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
15. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
16. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V
J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881
[TBL] [Abstract][Full Text] [Related]
17. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
18. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
19. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
20. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
